No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US Stock MarketDetailed Quotes
AQST Aquestive Therapeutics
- 3.650
- +0.010+0.27%
Close Dec 20 16:00 ET
- 3.689
- +0.039+1.07%
Post 19:59 ET
332.80MMarket Cap-8.04P/E (TTM)
3.770High3.520Low1.35MVolume3.560Open3.640Pre Close4.93MTurnover1.66%Turnover RatioLossP/E (Static)91.18MShares6.23052wk High-7.33P/B295.58MFloat Cap1.95052wk Low--Dividend TTM80.98MShs Float20.696Historical High--Div YieldTTM6.87%Amplitude0.618Historical Low3.661Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
H.C. Wainwright Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $10
Aquestive Therapeutics Gains Buy Rating Amid Orphan Drug Exclusivity and Promising Product Pipeline
Lake Street Reaffirms Their Buy Rating on Aquestive Therapeutics (AQST)
Aquestive Therapeutics Price Target Maintained With a $10.00/Share by HC Wainwright & Co.
Sector Update: Health Care Stocks Lower Thursday Afternoon
Aquestive Therapeutics Receives U.S. FDA Orphan Drug Exclusivity For Libervant Buccal Film In Pediatric Patients With Seizure Clusters Ages 2-5
Heat List
US
Overall
Symbol
Price
% Chg
No Data